达安基因(002030) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 reached ¥2,339,884,957.72, representing a 297.38% increase compared to ¥588,829,623.53 in the same period last year[8] - Net profit attributable to shareholders was ¥1,128,623,209.01, a significant increase of 505.59% from ¥186,368,214.09 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥1,112,981,665.53, up 517.41% from ¥180,267,370.20 in the previous year[8] - Basic earnings per share were ¥1.2867, reflecting a 505.51% increase from ¥0.2125 year-on-year[8] - The company's operating revenue for the reporting period reached CNY 2,339,884,957.72, a significant increase of 297.38% compared to CNY 588,829,623.53 in the previous year[29] - The net profit attributable to shareholders is projected to be between CNY 135,000,000 and CNY 165,000,000, representing a growth of 73.41% to 111.95% compared to CNY 77,849,270 in the same period last year[38] - The company reported a net cash flow from operating activities of CNY 692,043,744.56, up 229.46% from CNY 210,054,658.97 in the previous year[31] - The company reported a total profit for the current period of ¥1,325,012,296.25, compared to ¥218,586,973.29 in the previous period, showing an increase of approximately 505.5%[1] - The company's total comprehensive income for the current period was ¥1,134,776,587.05, compared to ¥183,534,807.04 in the previous period, reflecting an increase of approximately 518.5%[83] Cash Flow - The net cash flow from operating activities was ¥692,043,744.56, an increase from ¥210,054,658.97 in the previous period[94] - Cash inflow from operating activities totaled ¥1,922,464,869.24, up from ¥489,125,823.24 year-over-year[94] - Cash inflow from investment activities amounted to ¥903,192,865.94, with a net cash flow of ¥216,943,894.36, compared to a net outflow of ¥5,925,583.22 last year[97] - Cash flow from financing activities resulted in a net outflow of ¥133,731,670.65, compared to a net outflow of ¥67,544,239.52 in the previous year[97] - The ending balance of cash and cash equivalents was ¥1,646,594,321.62, up from ¥363,664,094.48 at the end of the previous period[97] - The company received ¥896,996,458.00 in cash from investment recoveries, a notable increase from ¥0.00 in the prior year[94] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,166,025,820.23, a 21.88% increase from ¥6,700,027,768.66 at the end of the previous year[8] - The total current assets reached ¥5,662,674,713.03, representing a growth of 31% compared to ¥4,327,332,175.75 at the end of 2020[56] - The total liabilities increased to ¥4,736,258,193.68, up from ¥4,232,719,505.23, indicating a growth of 11.9%[59] - The company's total assets as of March 31, 2021, were ¥6,820,543,114.97, up from ¥5,312,130,619.01 at the end of 2020, reflecting a growth of approximately 28.3%[69] - Total liabilities amounted to CNY 2,185,370,908.42, a decrease of CNY 47,053,882.77 from the previous period[114] - The total current liabilities stood at CNY 2.06 billion, with no changes from the previous year[110] Shareholder Information - The total number of shareholders at the end of the reporting period was 206,325, with the top ten shareholders holding a combined 38.13% of the shares[17] - The company reported a diluted earnings per share of ¥1.2867, calculated based on a total share capital of 877,153,770 shares[9] Research and Development - The company's R&D expenses increased by 116.20% to CNY 60,666,828.78, indicating a stronger focus on innovation[29] - Research and development expenses amounted to ¥60,666,828.78, up from ¥28,060,251.38, reflecting a growth of approximately 116.5%[1] Government Support - The company received government subsidies amounting to ¥24,233,750.13 during the reporting period[9] - The company received government grants and project-specific funding, resulting in other income increasing by 219.40% to CNY 24,233,750.13[31] Compliance and Governance - The company reported no non-compliance with external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[43][44] - The company has not declared any dividends or interest payable during the reporting period[126] Inventory and Accounts Receivable - The total accounts receivable rose to CNY 2,109,909,628.35, a 41.09% increase from CNY 1,495,395,013.86, driven by higher sales volume[29] - Accounts receivable increased to ¥2,109,909,628.35, up 41% from ¥1,495,395,013.86 in the previous period[53] - The company's inventory stood at ¥473,702,796.10, which is a 50.2% increase from ¥315,716,471.41 in the previous year[53] Financial Adjustments and Standards - The company has implemented new leasing standards, resulting in adjustments to the financial statements starting from January 1, 2021[104] - The company has recognized a lease liability of CNY 47,053,882.77 under the new leasing standards[126]